Title:The Effect of Intranasal Oxytocin on Sexual Function in Men and Women:
A Systematic Review
Volume: 18
Issue: 1
Author(s): Zahra Ghorbani and Mojgan Mirghafourvand*
Affiliation:
- Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Iran
Keywords:
Intranasal, oxytocin, sexual function, men, women, clinical trial.
Abstract:
Background: Intranasal oxytocin can be used as a promising moiety for the treatment of
sexual disorders.
Objective: This study was carried out to systematically review the effect of intranasal oxytocin on
sexual function in men and women.
Methods: We systematically searched databases (e.g., Cochrane Central Register of Controlled Trials
Library, MEDLINE, Web of Science, Scopus, ProQuest, Google Scholar and Persian databases). All
types of published clinical trials comparing different doses of intranasal oxytocin sprays with placebo
sprays were included in the study. The primary outcome was sexual function and secondary outcomes
were endocrine and cardiovascular measures and also side effects.
Results: A total of six studies were ultimately eligible for inclusion in the study. Though intranasal
oxytocin improves various parameters of sexual function in men and women, according to the sexual
response cycle, these changes are not statistically meaningful compared to the control group. Only one
study revealed a meaningful impact on orgasm parameters and after orgasm, especially in men. In all
studies, intranasal oxytocin administration has significantly and transiently increased plasma concentrations
of oxytocin with no meaningful effect on other endocrine hormones. A study showed that the
heartbeat is increased transiently during the arousal and orgasm stages, and such increase is meaningfully
higher in men than in women.
Conclusion: Intranasal oxytocin administration fails to meaningfully affect the classical parameters of
sexual response, but it improves the orgasmic and post-orgasmic dimensions, especially in men. To
evaluate the effects of intranasal oxytocin administrations, we need more long-term clinical trials.